Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind Phase IIb in 399 postmenopausal women with low BMD, the 3 higher doses of odanacatib met the primary
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury